Skip to main content

Advertisement

SpringerLink
Log in

Clinical trials

The silent minority—unpublished data on cancer care

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

From 1989 to 2003, 709 phase III trials evaluating systemic cancer treatment were presented at ASCO meetings. Tam and collaborators have now reported that 9% of these trials were never published, and 13% were published after a 5-year delay. More than half of these studies would have had clinical impact if published promptly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Smith, R. Classical peer review: an empty gun. Breast Cancer Res. 12 (Suppl. 4), S13 (2010).

    Article  Google Scholar 

  2. Tam, V. C., Tannock, I. F., Massey, C., Rauw, J. & Krzyzanowska, M. K. Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. J. Clin. Oncol. 29, 3133–3139 (2011).

    Article  Google Scholar 

  3. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).

    Article  CAS  Google Scholar 

  4. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).

    Article  CAS  Google Scholar 

  5. Joensuu, H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).

    Article  CAS  Google Scholar 

  6. Love, N. (Ed.) Patterns of care in medical oncology—Breast cancer edition. Vol. 1 (Research to Practice, Miami, 2005).

  7. Love, N. (Ed.) Patterns of care in medical oncology—Breast cancer edition. Vol. 2 (Research to Practice, Miami, 2005).

  8. Lefebvre, C., Manheimer, E. & Glanville, J. in Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (eds Higgins, J. P. T. & Green, S.) Ch. 6 (The Cochrane Collaboration[online], 2011).

    Google Scholar 

  9. [No authors listed] Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 365, 1687–1717 (2005).

  10. Andre, F. et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat. Rev. Clin. Oncol. 8, 171–176 (2011).

    Article  Google Scholar 

Download references

Acknowledgements

Supported in part by a grant from the Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale™.

Author information

Authors and Affiliations

  1. University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, 48109, MI, USA

    Daniel F. Hayes

Authors
  1. Daniel F. Hayes
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

D. F. Hayes declares he is a consultant for Biomarker Strategies and Chugai Pharmaceuticals and he receives research funding from Novartis, Pfizer and Veridex LLC. He also owns shares from Oncimmune. He has two pending patents regarding the use and development of assays for circulating tumor cells.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayes, D. The silent minority—unpublished data on cancer care. Nat Rev Clin Oncol 8, 631–632 (2011). https://doi.org/10.1038/nrclinonc.2011.148

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.148

  • Springer Nature Limited

Search

Navigation